Evidence map›Paper›PMID 31734719›Full record

ReviewGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2020

The role of Müller cell glucocorticoid signaling in diabetic retinopathy.

Farhad Ghaseminejad, Lew Kaplan, Anna M Pfaller, Stefanie M Hauck, Antje Grosche

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Role of microRNA-25 in high glucose cultured Müller glia.International journal of ophthalmology · 2021
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Farhad GhaseminejadDepartment of Physiological Genomics, Ludwig-Maximilians-Universität München, Großhaderner Str. 9, Martinsried, Germany.
Lew KaplanDepartment of Physiological Genomics, Ludwig-Maximilians-Universität München, Großhaderner Str. 9, Martinsried, Germany.
Anna M PfallerDepartment of Physiological Genomics, Ludwig-Maximilians-Universität München, Großhaderner Str. 9, Martinsried, Germany.
Stefanie M HauckResearch Unit Protein Science, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Heidemannstr. 1, Neuherberg, Germany.
Antje GroscheDepartment of Physiological Genomics, Ludwig-Maximilians-Universität München, Großhaderner Str. 9, Martinsried, Germany. Antje.Grosche@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-0338-7530
Ludwig-Maximilians-Universität München · DEHelmholtz Zentrum München · DE

Funding

Deutsche Forschungsgemeinschaft GR 4403/2-1Deutsche Forschungsgemeinschaft HA6014/5-1University of British Columbia UBC-Germany Scholarship
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a sight-threatening complication associated with the highly prevalent diabetes disorder. Both the microvascular damage and neurodegeneration detected in the retina caused by chronic hyperglycemia have brought special attention to Müller cells, the major macroglia of the retina that are responsible for retinal homeostasis. Given the role of glucocorticoid signaling in anti-inflammatory responses and the almost exclusive expression of glucocorticoid receptors (GRs) in retinal Müller cells, administration of corticosteroid agonists as a potential treatment option has been widely studied. Although these approaches have been moderately efficacious in treating or de-escalating DR pathomechanisms, there are various side effects and gaps of knowledge with regard to introducing exogenous glucocorticoids to the diseased retina. In this paper, we provide a review of the literature concerning the available evidence for the role of Müller cell glucocorticoid signaling in DR and we discuss previously investigated approaches in modulating this system as possible treatment options. Furthermore, we propose a novel alternative to the available choices of treatment by using gene therapy as a tool to regulate the expression of GR in retinal Müller cells. Upregulating GR expression allows for induced glucocorticoid signaling with more enduring effects compared to injection of agonists. Hence, repetitive injections would no longer be required. Lastly, side effects of glucocorticoid therapy such as glucocorticoid resistance of GR following chronic exposure to excess ligands or agonists can be avoided.

Indexed as

AnimalsDiabetic RetinopathyEpendymoglial CellsHumansReceptors, GlucocorticoidRetinaSignal TransductionReceptors, GlucocorticoidDiabetic retinopathyGene therapyGlucocorticoid signalingMüller cells

Identifiers

PMID31734719
OpenAlexW2987820958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.